AMRX · Amneal Pharmaceuticals, Inc.
$20.38
-0.49% last session
End-of-day data · close of 2026-10-23
Market cap
$7B
Enterprise value
$9B
Trailing P/E
41.6
Forward P/E
16.9
Dividend yield
0.0%
Beta
1.22
Avg volume
3M
Employees
9K
Daily Change %
-0.49%
5 Days Change
6.78%
10 Days Change
4.65%
30 Days Change
5.95%
60 Days Change
15.19%
Month to Day Change
2.04%
Year to Day Change
62.54%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AMRX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-22
Latest call per bank · past 12 months
JP Morgan
Overweight$24.00
+17.8% vs priceBarclays
Overweight$20.00
-1.9% vs priceUBS
Buy$25.00
+22.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | JP Morgan | Maintains | Overweight | $22.00 → $24.00 |
| 2026-09-23 | Oppenheimer | Initiates | Outperform | $0.00 → $27.00 |
| 2026-09-17 | Barclays | Maintains | Overweight | $16.00 → $20.00 |
| 2026-09-09 | Leerink Partners | Initiates | Outperform | $0.00 → $23.00 |
| 2026-08-03 | UBS | Maintains | Buy | $23.00 → $25.00 |
| 2026-07-15 | UBS | Maintains | Buy | $19.00 → $23.00 |
| 2026-05-20 | Barclays | Maintains | Overweight | $15.00 → $16.00 |
| 2026-04-17 | UBS | Initiates | Buy | $0.00 → $19.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 61 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 8.3% above the 50-day MA ($18.81).
- bullish: Price vs 200-day MA: Trading 31.1% above the 200-day MA ($15.54).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.00) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($20.50).
AMRX Price Chart
Loading chart for AMRX…
Fundamentals
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$65B 30.6% YTD
TEVA
Teva Pharmaceutical Industries
$46B 28.8% YTD
HLN
Haleon plc
$45B 4.6% YTD
ZTS
Zoetis Inc.
$33B -33.8% YTD
UTHR
United Therapeutics Corporation
$25B 20.0% YTD
VTRS
Viatris Inc.
$21B 51.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$15B 1.0% YTD
ELAN
Elanco Animal Health Incorporat
$11B 0.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.